5-cyclopropyl-4-[(1-naphthyl)methyl]-2-oxo-8-phenyl-7-thia-1-azabicyclo[4.3.0]nona-3,5,8-triene-9-carboxylic acid | 1235550-89-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-cyclopropyl-4-[(1-naphthyl)methyl]-2-oxo-8-phenyl-7-thia-1-azabicyclo[4.3.0]nona-3,5,8-triene-9-carboxylic acid
• 英文别名: 8-Cyclopropyl-7-(1-naphthylmethyl)-5-oxo-2-phenyl-thiazolo[3,2-a]pyridine-3-carboxylic acid；8-cyclopropyl-7-(naphthalen-1-ylmethyl)-5-oxo-2-phenyl-[1,3]thiazolo[3,2-a]pyridine-3-carboxylic acid
• CAS: 1235550-89-6
• 化学式: C₂₈H₂₁NO₃S
• 分子量: 451.546
• InChiKey: FOJPQRMSJTVRRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  82.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-cyclopropyl-4-[(1-naphthyl)methyl]-2-oxo-8-phenyl-7-thia-1-azabicyclo[4.3.0]nona-3,5,8-triene-9-carboxylic acid 、 N,N'-羰基二咪唑 以 二氯甲烷 为溶剂， 反应 1.75h， 生成
  参考文献：
  名称：

  Design and Synthesis of C-2 Substituted Thiazolo and Dihydrothiazolo Ring-Fused 2-Pyridones: Pilicides with Increased Antivirulence Activity

  摘要：

  Pilicides block pili formation by binding to pilus chaperones and blocking their function in the chaperone/usher pathway in E. coli. Various C-2 substituents were introduced on the pilicide scaffold by design and synthetic method developments. Experimental evaluation showed that proper substitution of this position affected the biological activity of the compound. Aryl substituents resulted in pilicides with significantly increased potencies as measured in pili-dependent biofilm and hemagglutination assays. The structural basis of the PapD chaperone-pilicide interactions was determined by X-ray crystallography.

  DOI：

  10.1021/jm100470t
• 作为产物：
  描述：

  8-cyclopropyl-7-(naphthalen-1-yl)methyl-5-oxo-2-phenyl-5H-thiazolo[3,2-a]pyridine-3-carboxylic acid methyl ester 在 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.42h， 以85%的产率得到5-cyclopropyl-4-[(1-naphthyl)methyl]-2-oxo-8-phenyl-7-thia-1-azabicyclo[4.3.0]nona-3,5,8-triene-9-carboxylic acid
  参考文献：
  名称：

  Design and Synthesis of C-2 Substituted Thiazolo and Dihydrothiazolo Ring-Fused 2-Pyridones: Pilicides with Increased Antivirulence Activity

  摘要：

  Pilicides block pili formation by binding to pilus chaperones and blocking their function in the chaperone/usher pathway in E. coli. Various C-2 substituents were introduced on the pilicide scaffold by design and synthetic method developments. Experimental evaluation showed that proper substitution of this position affected the biological activity of the compound. Aryl substituents resulted in pilicides with significantly increased potencies as measured in pili-dependent biofilm and hemagglutination assays. The structural basis of the PapD chaperone-pilicide interactions was determined by X-ray crystallography.

  DOI：

  10.1021/jm100470t

文献信息

• [EN] RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF TUBERCULOSIS<br/>[FR] THIAZOLINO 2-PYRIDONES À CYCLES FUSIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE LA TUBERCULOSE
  申请人：QURETECH BIO AB

  公开号：WO2017175182A1

  公开（公告）日：2017-10-12

  The present disclosure provides a combination comprising: (i) a drug against tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula (II), or a pharmaceutically acceptable combination thereof. The combination may be used in the treatment and/or prevention of tuberculosis.

  本公开提供了一种组合物，包括：（i）用于治疗结核病的药物或其药用盐，以及（ii）式（II）的化合物，或其药用可接受的组合物。该组合物可用于治疗和/或预防结核病。
• [EN] RING-FUSED THIAZOLINO 2-PYRIDONES IN COMBINATION WITH A DRUG AGAINST TUBERCULOSIS<br/>[FR] THIAZOLINO 2-PYRIDONES À CYCLE FUSIONNÉ EN COMBINAISON AVEC UN MÉDICAMENT CONTRE LA TUBERCULOSE
  申请人：QURETECH BIO AB

  公开号：WO2019068910A1

  公开（公告）日：2019-04-11

  The present disclosure provides a combination comprising: (i). a drug against tuberculosis inhibiting the cytochrome b subunit of the bc1 complex, said cytochrome b subunit being encoded by the gene qcrB,in Mycobacterium tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

  本公开提供一种组合物，包括：(i) 抗结核药物，抑制bc1复合物的细胞色素b亚基，所述细胞色素b亚基由Mycobacterium tuberculosis的qcrB基因编码，或其药用盐，以及(ii) 公式(II)的化合物，或其药用盐。
• [EN] RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA<br/>[FR] THIAZOLINO 2-PYRIDONES À CYCLES FUSIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIE IMPLIQUANT DES BACTÉRIES À GRAM POSITIF
  申请人：QURETECH BIO AB

  公开号：WO2018229141A1

  公开（公告）日：2018-12-20

  The present disclosure provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, optionally in combination with a drug against a disease involving gram-positive bacteria.

  本公开提供一种I式化合物，或其药学上可接受的盐，可选地与一种针对涉及革兰氏阳性细菌疾病的药物组合使用。
• Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
  申请人：QURETECH BIO AB

  公开号：US10945999B2

  公开（公告）日：2021-03-16

  The present disclosure provides a combination comprising: (i) a drug against tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II, or a pharmaceutically acceptable combination thereof. The combination may be used in the treatment and/or prevention of tuberculosis.

  本公开提供了一种组合物，包括：(i) 抗结核药物或其药学上可接受的盐；(ii) 式 II.化合物或其药学上可接受的组合物、 或其药学上可接受的组合物。 该组合物可用于治疗和/或预防结核病。
• Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis
  申请人：QURETECH BIO AB

  公开号：US11129816B2

  公开（公告）日：2021-09-28

  Described is a composition that includes: (i) a drug against tuberculosis inhibiting the cytochrome b subunit of the bc1 complex, said cytochrome b subunit being encoded by the gene qcrB, in Mycobacterium tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II, or a pharmaceutically acceptable salt thereof.

  所述组合物包括 (i) 一种抑制 bc1 复合物细胞色素 b 亚基的抗结核药物，所述细胞色素 b 亚基由结核分枝杆菌中的 qcrB 基因编码，或其药学上可接受的盐，和 (ii) 式 II 的化合物、 或其药学上可接受的盐。